SCHEMBL6783558

SCHEMBL6783558

COC(=O)c1ccc(C(=O)NCc2c[nH]cn2)cc1NC(=O)/C=C(/C)c1ccc2ccccc2c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.48
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 3/20 0.42
ALOX12 P18054 1/20 0.42
ATM Q13315 2/20 0.39
GAA P10253 2/20 0.39
GLA P06280 1/20 0.39
HPGD P15428 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
NR1H4 Q96RI1 3/20 0.38
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
KMT2A Q03164 1/20 0.37
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6787438 0.92 TERT (0.58) TERTKDM4ENPC1RAB9ANR1H4
SCHEMBL6783769 0.87 TERT (0.50) TERTKDM4EALDH1A1ALOX12HPGD
SCHEMBL6787657 0.84 TERT (0.56) TERTKDM4EALDH1A1ALOX12ATM
SCHEMBL6787673 0.83 TERT (0.57) TERTKDM4EALDH1A1ALOX12ATM
SCHEMBL6787847 0.83 TERT (0.51) TERTKDM4EALDH1A1ALOX12NPC1
SCHEMBL6781509 0.82 TERT (0.55) TERTKDM4EALDH1A1ALOX12ATM
SCHEMBL6787103 0.82 TERT (0.55) TERTKDM4EALDH1A1ALOX12ATM
SCHEMBL6787693 0.82 TERT (0.55) TERTKDM4EALDH1A1ALOX12ATM
SCHEMBL6786930 0.82 TERT (0.55) TERTKDM4EALDH1A1ALOX12ATM
SCHEMBL6785336 0.82 TERT (0.55) TERTKDM4EALDH1A1ALOX12ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885KDM4E 1243/4885ALDH1A1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.